ABT Stock Up 6.4% after 6-Day Win Streak
Abbott Laboratories (ABT) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 6.4% return. The company has gained about $15 Bil in value over the last 6 days, with its current market capitalization at about $234 Bil. The stock remains 20.4% above its value at the end of 2024. This compares with year-to-date returns of 8.6% for the S&P 500.
ABT develops and sells healthcare products across pharmaceuticals, diagnostics, nutrition, and medical devices, specializing in cardiovascular treatments and related technologies. After this rally, is ABT still a buy – or is it time to lock in gains? Deep dive with Buy or Sell ABT.
Comparing ABT Stock Returns With The S&P 500
The following table summarizes the return for ABT stock vs. the S&P 500 index over different periods, including the current streak:
- Why RMD Could Outperform Abbott Laboratories Stock
- Better Value & Growth: RMD, BDX Lead Abbott Laboratories Stock
- RMD, BDX Top Abbott Laboratories Stock on Price & Potential
- Better Value & Growth: RMD, BDX Lead Abbott Laboratories Stock
- Pay Less, Grow More: RMD, BDX Outshine Abbott Laboratories Stock
- Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX
| Return Period | ABT | S&P 500 |
|---|---|---|
| 1D | 1.7% | 0.8% |
| 6D (Current Streak) | 6.4% | 0.8% |
| 1M (21D) | 0.5% | 1.7% |
| 3M (63D) | 0.7% | 12.8% |
| YTD 2025 | 20.4% | 8.6% |
| 2024 | 4.8% | 23.3% |
| 2023 | 2.3% | 24.2% |
| 2022 | -20.7% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 60 S&P constituents with 3 days or more of consecutive gains and 48 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 36 | 27 |
| 4D | 4 | 19 |
| 5D | 14 | 0 |
| 6D | 5 | 0 |
| 7D or more | 1 | 2 |
| Total >=3 D | 60 | 48 |
Key Financials for Abbott Laboratories (ABT)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $40.1 Bil | $42.0 Bil |
| Operating Income | $6.5 Bil | $6.8 Bil |
| Net Income | $5.7 Bil | $13.4 Bil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $11.0 Bil | $10.4 Bil |
| Operating Income | $1.9 Bil | $1.7 Bil |
| Net Income | $9.2 Bil | $1.3 Bil |
While ABT stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.